Retrospective Study on the Incidence and Management of Anemia in Oncology

Weprom349 enrolled

Overview

The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies). Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management. Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.

Study Type

OBSERVATIONAL

Enrollment

349

Conditions

Anemia Cancer

Interventions

anemia assessmentOTHER

evaluation of anemia status

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years old, * Follow-up for cancer justifying hospitalization, * Presenting anemia defined by a hemoglobin level \<11 g / dL, * Patient not having objected to the collection of his data after oral and written information. Exclusion Criteria: * patients with a hemoglobin level ≥ 11 g / dL, * adult patients under guardianship, curatorship or deprived of liberty, * pregnancy or breast-feeding in progress at the time of hospitalization.

Outcomes

Primary Outcomes

Incidence of anemia

number of patient with anemia (\<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period

Time frame: 2 years

Secondary Outcomes

Assessment of transfusion prescriptions

number of transfusions performed on the number of patients hospitalized over the period

Time frame: 2 years

Assessment of erythropoiesis stimulating agents (EPO) prescriptions

number of prescriptions for erythropoiesis stimulating agents (EPO)

Time frame: 2 years

Assessment of iron prescriptions

number of prescriptions of iron (oral and intravenous)

Time frame: 2 years

Time between last transfusion and date of death

Delay between the date of the last transfusion and the date of patient's death

Time frame: 2 years

overall survival

Delay between the enrollment date and the date of patient's death

Time frame: 2 years

Retrospective Study on the Incidence and Management of Anemia in Oncology

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes